- Home
- ICE vs DMAC Comparison
ICE vs DMAC Comparison
Compare ICE & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICE
- DMAC
- Stock Information
- Founded
- ICE 2000
- DMAC 2000
- Country
- ICE United States
- DMAC United States
- Employees
- ICE N/A
- DMAC N/A
- Industry
- ICE Investment Bankers/Brokers/Service
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- ICE Finance
- DMAC Health Care
- Exchange
- ICE Nasdaq
- DMAC Nasdaq
- Market Cap
- ICE N/A
- DMAC 178.0M
- IPO Year
- ICE 2005
- DMAC N/A
- Fundamental
- Price
- ICE $183.11
- DMAC $3.76
- Analyst Decision
- ICE Strong Buy
- DMAC Strong Buy
- Analyst Count
- ICE 14
- DMAC 2
- Target Price
- ICE $188.43
- DMAC $8.00
- AVG Volume (30 Days)
- ICE 2.3M
- DMAC 307.4K
- Earning Date
- ICE 07-31-2025
- DMAC 08-06-2025
- Dividend Yield
- ICE 1.05%
- DMAC N/A
- EPS Growth
- ICE 10.92
- DMAC N/A
- EPS
- ICE 4.83
- DMAC N/A
- Revenue
- ICE $9,462,000,000.00
- DMAC N/A
- Revenue This Year
- ICE $8.30
- DMAC N/A
- Revenue Next Year
- ICE $5.67
- DMAC N/A
- P/E Ratio
- ICE $37.91
- DMAC N/A
- Revenue Growth
- ICE 12.88
- DMAC N/A
- 52 Week Low
- ICE $139.61
- DMAC $2.80
- 52 Week High
- ICE $183.76
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- ICE 63.15
- DMAC 47.18
- Support Level
- ICE $179.31
- DMAC $3.48
- Resistance Level
- ICE $183.76
- DMAC $3.99
- Average True Range (ATR)
- ICE 2.41
- DMAC 0.32
- MACD
- ICE 0.04
- DMAC -0.00
- Stochastic Oscillator
- ICE 89.70
- DMAC 41.01
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.